慢性丙型肝炎患者Ⅰ型干扰素受体启动子基因多态性与抗病毒疗效的关系

周莉; 郄春花; 郭洁; 陆伟; 王怡; 高敏; 卢诚震; 韩旭; 翟璐

慢性丙型肝炎患者Ⅰ型干扰素受体启动子基因多态性与抗病毒疗效的关系

1. 天津市肝病研究所
2. 天津市传染病医院肝病科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 3009
- HTML全文浏览量: 5
- PDF下载量: 642
- 被引次数: 0
出版历程
- 出版日期: 2012-05-20

Association between the type Ⅰinterferon receptor promoter gene and treatment response to antivirus in patients with chronic hepatitis C

摘要

摘要: 目的研究慢性丙型肝炎（CHC）患者Ⅰ型干扰素受体之一IFNAR1启动子基因的单核苷酸多态性与干扰素（IFN）α抗HCV疗效的关系。方法应用聚乙二醇干扰素α联合利巴韦林抗HCV治疗,根据抗病毒疗效将73例患者分为应答组与无应答组,并对其IFNAR1启动子基因进行扩增及测序。结果 73例患者中应答组47例,无应答组26例,在-568、-408、-77、-3位点发现基因多态性,共10种基因单体型,其中单体型-568C/-408C/-77（GT）5/-3C和-568C/-408T/-77（GT）5/-3T出现频率最高。非-568C/-408C/-77（GT）5/-3C者的抗病毒应答率77.1%高于-568C/-408C/-77（GT）5/-3C者52.6%,（χ2=4.773,P=0.029）,-568C/-408T/-77（GT）5/-3T者的抗病毒应答率90.9%高于非-568C/-408T/-77（GT）5/-3T者59.7%,（χ2=3.92,P=0.048）。结论 CHC患者IFNAR1启动子基因多态性可能影响IFNα抗HCV治疗应答。
- 肝炎,丙型,慢性 /
- 受体,干扰素 /
- 多态性,单核苷酸
Abstract: Objective To investigate the association between polymorphisms of type Ⅰinterferon receptor (IFNAR1) promoter gene and the treatment response to interferon alpha (IFNα) in patients with chronic hepatitis C (CHC) .Methods 73 CHC patients who consented to receive pegylated IFNα in combination with ribavirin therapy were enrolled in this study.The treatment responses were monitored.The subjects were divided into two groups as response and no response.Meanwhile, the genes of IFNAR1 promoter in these patients were sequenced.Measurement data were analyzed by t test and enumeration data were analyzed by Chi square test.Results 47 patients achieved response and 26 patients had no response.Polymorphisms were identified in IFNAR1 promoter gene, which include G/C substitution at locus-568, C/T substitution at locus-408, C/T substitution at locus-3 and GT microsatellite repeat sequence at locus-77.The response rate to antivirus therapy in CHC patients with haplotype non-568C/-408C/-77 (GT) 5/-3C was higher than that in patients with haplotype-568C/-408C/-77 (GT) 5/-3C (77.1% vs 52.6%, χ2=4.773, P=0.029) .The response rate to antivirus therapy in CHC patients with haplotype-568C/-408T/-77 (GT) 5/-3T was higher than that in patients with haplotype non-568C/-408T/-77 (GT) 5/-3T (90.9% vs 59.7%, χ2=3.92, P=0.048) .Conclusion Polymorphisms of IFNAR1 promoter gene are associated with the treatment response to IFNα in CHC patients.
- hepatitis C /
- chronic /
- receptor

HTML全文

参考文献(10)

[1]慢性丙型肝炎抗病毒治疗专家委员会.慢性丙型肝炎抗病毒治疗专家共识[J/CD].中华实验和临床感染病杂志 (电子版) , 2009, 3 (3) :343-352.

[2] UzéG, Schreiber G, Piehler J, et al.The receptor of the typeIinterferon family[J].Curr Top Microbiol Immunol, 2007, 316:71-95.

[3]Mogensen KE, Lewerenz M, Reboul J, et al.The typeⅠin-terferon receptor:structure, function, and evolution of afamily business[J].Interferon Cytokine Res, 1999, 19:1069-1098.

[4]中华医学会肝病学分会, 中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南[J].中华传染病杂志, 2004, 22 (2) :131-136.

[5]周婕, 吕力为, 张斌, 等.Ⅰ型干扰素受体启动子多态性与慢性乙型肝炎易感性的相关性研究[J].微生物与感染, 2007, 2 (1) :19-25.

[6]Tena-Tomás C, Pedroso ML, Kremsner PG, et al.Polymor-phisms in the IFNAR1 gene in patients with chronic hepatitisC:outcome of combined IFN-alpha therapy[J].Eur Cyto-kine Netw, 2007, 18 (3) :136-141.

[7]Zhou J, Smith DK, Lu L, et al.A non-synonymous singlenucleotide polymorphism in IFNAR1 affects susceptibility tochronic hepatitis B virus infection[J].J Viral Hepat, 2009, 16 (1) :45-52.

[8]He XX, Chang Y, Jiang HJ, et al.Persistent effect of IFNAR-1 genetic polymorphism on the long-term pathogenesis ofchronic HBV infection[J].Viral Immunol, 2010, 23 (3) :251-257.

[9]Yoshida K, Alagbe O, Wang X, et al.Promoter polymor-phisms of the interferon-alpha receptor gene and develop-ment of Interferon-induced depressive symptoms in pa-tients with chronic hepatitis C:preliminary findings[J].Neu-ro-psychobiology, 2005, 52 (2) :55-61.

[10]Zhou J, Lu L, Yuen MF, et al.Polymorphisms of type I interfer-on receptor 1 promoter and their effects on chronic hepatitis Bvirus infection[J].J Hepatol, 2007, 46 (2) :198-205.

施引文献

资源附件(0)

访问统计